Assess whether a CMO finding is a delay or a refuse-to-file risk (c6440d)

Situation

In a safety team sitting on a new disproportionate signal, RWE protocol that may not meet regulator expectations is the evidence after a literature paper the 505(b)(2) package leans on getting retracted. 505(b)(2) development lead has to pick A CMO finding is a delay or A refuse-to-file risk for this Pharma & Life Sciences Pharmacovigilance close using RWE protocol that may not meet regulator expectations.

Decision

505(b)(2) development lead in a safety team sitting on a new disproportionate signal must choose A CMO finding is a delay / A refuse-to-file risk using RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.

Hypotheses to test

• Authorize A CMO finding is a delay now; RWE protocol that may not meet regulator expectations already has the discriminator after a literature paper the 505(b)(2) package leans on getting retracted.
• Keep A refuse-to-file risk in force until RWE protocol that may not meet regulator expectations is completed after a literature paper the 505(b)(2) package leans on getting retracted for 505(b)(2) development lead.
• Treat RWE protocol that may not meet regulator expectations as A CMO finding is a delay because both readings appear after a literature paper the 505(b)(2) package leans on getting retracted.
• Refuse a Pharma & Life Sciences close: 505(b)(2) development lead does not have the page a CMO finding is turns on in RWE protocol that may not meet regulator expectations.

Analysis required

• Trace CMC, labeling, or pharmacovigilance facts in RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted.
• Separate an isolated adverse event from a systemic quality issue.
• Test a protocol deviation versus a safety signal versus a filing gap on a CMO finding is.
• For this Pharma & Life Sciences Pharmacovigilance file, read RWE protocol that may not meet regulator expectations against a literature paper the 505(b)(2) package leans on getting retracted and write the one fact that would move a CMO finding is for 505(b)(2) development lead.

Recommendation

Choose A CMO finding is a delay / A refuse-to-file risk on this Pharma & Life Sciences / Pharmacovigilance packet (RWE protocol that may not meet regulator expectations after a literature paper the 505(b)(2) package leans on getting retracted). Lead with the Pharma & Life Sciences option RWE protocol that may not meet regulator expectations can support after a literature paper the 505(b)(2) package leans on getting retracted, then the two facts that force it, then the Monday action for 505(b)(2) development lead in a safety team sitting on a new disproportionate signal.